VivoSim Labs
Innovative San Diego-based company specializing in 3D bioprinting for medical research and therapy.
Founded
2011Innovative San Diego-based company specializing in 3D bioprinting for medical research and therapy.
Founded in 2007 and headquartered in San Diego, California, Organovo Holdings, Inc. is a pioneering biotech company specializing in 3D bioprinting technology. The company's core mission is to create functional, three-dimensional human tissues for medical research and therapeutic applications. Organovo's innovative bioprinting solutions are designed to enhance drug discovery processes and offer potential advancements in regenerative medicine. Serving a global market, the company aims to revolutionize the way researchers and clinicians approach tissue engineering and disease modeling.
Notable figures associated with Organovo include Taylor J. Crouch, who has served as CEO. The company is publicly traded on Nasdaq under the ticker symbol ONVO and is a component of the Russell 2000 Index. Organovo has achieved significant milestones, including presenting groundbreaking data at major medical conferences such as Digestive Disease Week. With total assets of over $62 million as of 2016 and a revenue of $4.23 million in 2017, Organovo continues to make a substantial impact in the biotech industry by advancing the capabilities of 3D bioprinting technology.
Companies similar to VivoSim Labs include 3DBio, Ortuvo, Precise Bio and Systemic Bio.
VivoSim Labs was founded in 2011.
VivoSim Labs' headquarters is located in San Diego, CA, US.
VivoSim Labs' most recent funding round was for $22M (USD) in January 2021.
As of Jan 29, 2021, VivoSim Labs has disclosed funding of $112.3M (USD). Undisclosed round amounts are excluded.
VivoSim Labs has 39 employees as of Feb 6, 2024.
systemic.bio
